How do you learn to love your body while struggling with a rare illness? I used to ask myself this almost daily. I love to eat, and comfort food provides just that — comfort. Vegetables and fruits sound delicious, but they wouldn’t be the first thing I run to…
Changes in gene activity and immune cell populations in the lungs of people with chronic lung diseases, such as idiopathic pulmonary fibrosis (IPF), may predispose these patients to severe COVID-19, a study indicated. “Our results suggest that patients with chronic lung disease are molecularly primed to be more susceptible…
A new, automated computer image analysis technique was able to accurately assess and measure the severity of pulmonary fibrosis (PF) using patients’ lung tissue samples, a study reported. According to its researchers, this technique may complement conventional measures of disease severity, and could prove useful in assessing a range…
In the three weeks between my boyfriend Jonny’s proposal and our spontaneous elopement, we daydreamed about a big wedding. We decided to get married before he left for a year of training and school with the Army. Despite our legal union, we still wanted to celebrate with a ceremony of…
The Washington Research Foundation (WRF) has awarded a $250,000 grant to support the development of a novel miniprotein binder to help treat idiopathic pulmonary fibrosis (IPF). The grant was awarded to Anindya Roy, PhD, an acting instructor and senior fellow at the University of…
Nominations are now open for the worldwide 2022 Black Pearl Awards from Eurordis-Rare Diseases Europe. The 12 award categories recognize individual advocates, policy makers, researchers, organizations, and companies who work to make a difference for the global rare disease community. The deadline for nominations is Sept. 10…
Excessive amounts of inflammation in the body often accompany chronic illness. For people living with idiopathic pulmonary fibrosis (IPF), a progressive and life-threatening lung disease, effectively managing inflammation is important to overall health and is a popular topic of discussion among IPF patients in our Pulmonary Fibrosis News Forums.
Enrollment has resumed, under a revised trial protocol, in the Phase 2b study GALACTIC-1, which is evaluating Galecto’s investigational inhaled therapy GB0139 in adults with idiopathic pulmonary fibrosis (IPF). Galecto in March had been advised to stop recruiting and treating certain trial participants after disparities were…
In February of 2016, I joined the Greater Kansas City Pulmonary Fibrosis Support Group. As I attended more meetings, I realized PF awareness was important, and I wanted to make a difference. Because I had a unique case of idiopathic pulmonary fibrosis (IPF) with ossification that excluded me from…
NeRRe Therapeutics has raised £20 million (nearly $28 million) to develop orvepitant as a treatment for the chronic cough that can impact quality of life for people with idiopathic pulmonary fibrosis (IPF). Orvepitant’s efficacy has been demonstrated in patients with refractory or unexplained chronic cough associated with reflex…
Get regular updates to your inbox.
